Augmenix lands $6.1 million in Series B round

October 19, 2009 by MassDevice staff

Amar Sawhney's latest hydrogel venture lands financing to take its SpaceOAR radiation oncology polymer product into clinical trials and commercialization.

Augmenix lands $6.1 million in Series B round

Augmenix, the latest life science venture from serial hydrogel entrepreneur Amar Sawhney, landed a second, $6.1 million tranche for a Series B funding round to develop its SpaceOAR radiation oncology polymer product.

Waltham, Mass.-based Augmenix is working on clinical trials for the product, an injectable, degradable polyethylene glycol-based hydrogel designed to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp